- Previous Close
604.00 - Open
606.00 - Bid 590.00 x --
- Ask 598.00 x --
- Day's Range
598.00 - 606.00 - 52 Week Range
462.00 - 660.00 - Volume
41 - Avg. Volume
52 - Market Cap (intraday)
18.398B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
11.62 - EPS (TTM)
51.46 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield 32.21 (4.99%)
- Ex-Dividend Date Jul 23, 2024
- 1y Target Est
--
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular, alimentary tract and metabolism, central nervous system, infections, oncology, and other diseases. The company also provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others. In addition, it offers animal health products comprising analgesics antimicrobials, antiparasitics, disinfectants, vitamins, and minerals. Further, the company provides health resort and tourist services. Krka, d. d. was founded in 1954 and is headquartered in Novo Mesto, Slovenia.
www.krka.si12,675
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: KRK.WA
View MorePerformance Overview: KRK.WA
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRK.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRK.WA
View MoreValuation Measures
Market Cap
18.38B
Enterprise Value
15.30B
Trailing P/E
11.73
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.29
Price/Book (mrq)
1.79
Enterprise Value/Revenue
1.89
Enterprise Value/EBITDA
6.74
Financial Highlights
Profitability and Income Statement
Profit Margin
17.65%
Return on Assets (ttm)
8.71%
Return on Equity (ttm)
14.43%
Revenue (ttm)
1.83B
Net Income Avi to Common (ttm)
323.81M
Diluted EPS (ttm)
51.46
Balance Sheet and Cash Flow
Total Cash (mrq)
563.62M
Total Debt/Equity (mrq)
0.56%
Levered Free Cash Flow (ttm)
16.76M